Research
BPC-157 Peptide: Research Overview, Dosing Calculations & Where to Source It
BPC-157 Peptide:
Research Overview, Dosing Calculations
& Where to Source It
A comprehensive research guide to Body Protection Compound-157 — covering molecular structure, mechanism of action, reconstitution protocols, an interactive dosing calculator, and how to source research-grade BPC-157 with verified purity.
What Is BPC-157 Peptide?
BPC-157 — formally known as Body Protection Compound-157 — is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a partial sequence of Body Protection Compound (BPC), a protein found endogenously in human gastric juice. The synthetic version used in research is designated PL-10 in some literature.
The full amino acid sequence of BPC-157 is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. This 15-residue sequence is notable for its high proline content, which contributes to its structural rigidity and resistance to degradation — making it substantially more stable in gastric acid than the full BPC protein from which it is derived.
BPC-157 was first described in peer-reviewed literature in the early 1990s, primarily by researcher Predrag Sikiric and colleagues at the University of Zagreb, whose group has published the majority of the preclinical research on this compound across several decades. The compound has been studied exclusively in in vitro settings and animal models — it has not received regulatory approval as a drug in any jurisdiction.
| Property | Value | Notes |
|---|---|---|
| IUPAC Name | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | 15-amino acid sequence |
| CAS Number | 137525-51-0 | Verified on Certificate of Analysis |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ | Confirmed by LC-MS |
| Molecular Weight | 1,419.55 g/mol | Exact mass: 1418.69 |
| Appearance | White lyophilized powder | Lyophilized for stability |
| Solubility | Water-soluble | Soluble in BAC water, saline, PBS |
| Storage (lyophilized) | −20°C to −80°C | Avoid light and moisture |
Mechanism of Action in Preclinical Research
The precise mechanism of action of BPC-157 remains an area of active investigation. Preclinical data suggests that BPC-157 interacts with several biological pathways simultaneously, which may explain the breadth of effects observed across different tissue systems in animal research. The following mechanisms have been proposed and studied in peer-reviewed literature:
Research in animal models suggests BPC-157 may upregulate endothelial nitric oxide synthase (eNOS) and interact with the NO system. This has been proposed as a mechanism by which the compound influences vascular biology and tissue perfusion in preclinical models.
Several studies report that BPC-157 may modulate the expression of growth factors including VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor), potentially contributing to angiogenic and proliferative effects observed in in vitro wound healing models.
In vitro research suggests BPC-157 may influence actin-cytoskeleton dynamics and FAK (focal adhesion kinase) signaling, which could contribute to observed effects on cell migration and fibroblast activity in culture models.
Animal model research has explored BPC-157’s interactions with dopaminergic and serotonergic signaling pathways. Some studies suggest the compound may modulate neurotransmitter systems, though the significance of these findings remains under investigation.
Studies using tendon fibroblast cultures have reported that BPC-157 may stimulate migration and survival of tenocytes. This has generated interest in musculoskeletal research applications, with several animal studies evaluating BPC-157 in tendon and ligament models.
As a compound derived from gastric BPC, BPC-157 has been extensively studied for gastrointestinal effects in rodent models. Research has examined its influence on GI mucosal integrity, ulcer biology, and gut motility in animal models.
Primary Research Areas for BPC-157
Based on the peer-reviewed literature, the following biological areas have been most studied in connection with BPC-157 in preclinical settings:
BPC-157 Reconstitution Protocol
BPC-157 is supplied as a lyophilized (freeze-dried) white powder in sealed research vials. Before use in any research application, the compound must be reconstituted in an appropriate aqueous diluent. The reconstitution process directly determines the working concentration and must be performed precisely.
BPC-157 Dosing Calculator
Use this calculator to determine the exact volume to draw from your reconstituted BPC-157 vial for a given research dose. Enter your vial size, diluent volume, and desired dose to get instant results.
BPC-157 Concentration Calculator
For research use only — not for human dosing guidance
BPC-157 Storage Guidelines
Proper storage is critical to maintaining BPC-157 integrity. As a peptide, BPC-157 is susceptible to degradation from heat, light, moisture, and repeated freeze-thaw cycling. The following guidelines apply to research-grade BPC-157 vials.
| Condition | Do ✓ | Avoid ✕ |
|---|---|---|
| Temperature | Store at or below −20°C (lyophilized) | Room temperature storage of lyophilized peptide |
| Light | Store in amber vial or wrapped in foil | Direct UV or fluorescent light exposure |
| Freeze-thaw | Aliquot reconstituted solution before freezing | Repeated freeze-thaw cycles (degrades peptide) |
| Moisture | Keep vial sealed until use; use desiccant | Exposing lyophilized powder to humidity |
| Reconstituted | Store at 2–8°C in BAC water for ≤4 weeks | Storing reconstituted peptide at room temperature |
Where to Buy BPC-157 for Research
Researchers sourcing BPC-157 for sale must prioritize verified purity, transparent testing documentation, and a supplier that clearly operates as a Research Use Only (RUO) chemical supplier rather than a compounding pharmacy. The market contains a wide range of quality — understanding what distinguishes a credible supplier is essential for data integrity.
What to Verify Before Purchasing BPC-157
| Quality Indicator | Why It Matters | BioLongevity Labs |
|---|---|---|
| HPLC Purity Certificate | Confirms peptide purity %. Lower purity = more impurities affecting results | 99%+ — Included |
| LC-MS Identity Verification | Confirms molecular weight matches BPC-157, not a different compound | Yes — On COA |
| Independent 3rd-Party Lab | In-house testing only = potential conflict of interest; 3rd-party = objective | Yes — Certified Lab |
| Endotoxin Testing | Critical for cell culture work — endotoxins skew biological assay results | Yes — LAL Method |
| COA Available Pre-Purchase | Allows verification before ordering — not hidden until after payment | Yes |
| RUO Compliance | Legal compliance — not sold as a drug or for human use | Fully Compliant |
| Lot Traceability | Each batch has a unique lot number tied to its COA for auditing | Yes — Per Batch |
| Zero Fillers or Additives | Fillers dilute active compound and introduce variables | Pure Compound Only |
Red Flags When Sourcing BPC-157
- No COA provided or COA is only available on request after payment
- Purity below 98% — acceptable for some industrial applications but not for reproducible biological research
- In-house testing only with no independent laboratory listed on the COA
- No RUO declaration — suppliers not clearly marking products as Research Use Only may not be compliant with applicable chemical supply regulations
- Implausibly low prices — legitimate synthesis, lyophilization, and independent testing have real costs; unusually cheap BPC-157 often reflects lower purity or no meaningful quality control
- Health claims or therapeutic language on the product page — a compliant RUO supplier does not describe products as treating, curing, or preventing any condition
BPC-157 in the Preclinical Research Landscape
The body of preclinical research on BPC-157 is substantial by peptide research standards. As of 2026, the compound has been referenced in over 180 indexed peer-reviewed publications, the large majority of which are animal model studies. The research is concentrated in several organ system categories:
Gastrointestinal Research
The largest volume of BPC-157 research focuses on gastrointestinal biology, consistent with the compound’s origin from gastric BPC. Studies have examined the compound’s effects on gastric and duodenal ulcer models in rodents, intestinal anastomosis healing, short bowel syndrome models, and GI motility. This represents the most mature preclinical literature base for the compound.
Musculoskeletal & Tendon Research
A significant body of animal model research has examined BPC-157’s effects in tendon, ligament, and bone injury models. Multiple rodent studies have used standardized tendon transection or crush injury models to evaluate healing endpoints. This has made musculoskeletal applications one of the most discussed areas in BPC-157 research.
Neurological & Systemic Research
More recent publications have investigated BPC-157’s effects on dopaminergic and serotonergic signaling in animal behavioral models, as well as its interactions with systemic stress responses. These represent an emerging area of preclinical inquiry that is less mature than the GI and musculoskeletal literature.
Research Publication Characteristics
| Research Category | Volume of Literature | Model Type | Maturity |
|---|---|---|---|
| Gastrointestinal biology | ~60+ studies | Primarily rodent in vivo | Most Mature |
| Musculoskeletal / tendon | ~40+ studies | Rodent tendon/bone models | Established |
| Wound healing / skin | ~20+ studies | In vitro + in vivo | Established |
| Neurological / CNS | ~25+ studies | Rodent behavioral models | Emerging |
| Vascular / angiogenesis | ~15+ studies | In vitro + rodent | Emerging |
| Systemic / other | ~20+ studies | Various animal models | Emerging |
Frequently Asked Questions
Legal Disclaimer & Research Use Only Notice
Not for Human Use: BPC-157 and all products on this page are sold for Research Use Only (RUO). They are intended solely for basic scientific research, pharmaceutical research, or the development of new tests — not for diagnosing, treating, curing, or preventing any disease or condition in any patient. These products are not drugs or medications.
Chemical Supplier Statement: BioLongevity Labs is a chemical supplier — not a compounding pharmacy or outsourcing facility as defined under 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
Content Disclaimer: All scientific information on this page is for educational and research context only. References to preclinical research findings do not constitute claims about human efficacy or safety. Customers are responsible for compliance with all applicable laws in their jurisdiction.
